Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of JNJ-64179375 in Healthy Japanese Subjects
NCT03080987Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ichorcumab in venous thromboembolism (VTE) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. Started Jun 2017; status: completed.
02
Drugs
ichorcumab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03080987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080987.